TW200630083A - Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract - Google Patents

Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract

Info

Publication number
TW200630083A
TW200630083A TW094136193A TW94136193A TW200630083A TW 200630083 A TW200630083 A TW 200630083A TW 094136193 A TW094136193 A TW 094136193A TW 94136193 A TW94136193 A TW 94136193A TW 200630083 A TW200630083 A TW 200630083A
Authority
TW
Taiwan
Prior art keywords
disorders
prostate
treatment
beta
agonist
Prior art date
Application number
TW094136193A
Other languages
English (en)
Chinese (zh)
Inventor
Martin Michel
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE102004050952A external-priority patent/DE102004050952A1/de
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200630083A publication Critical patent/TW200630083A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW094136193A 2004-10-18 2005-10-17 Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract TW200630083A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004050952A DE102004050952A1 (de) 2004-10-18 2004-10-18 Pharmazeutische Zusammensetzung zur Behandlung von Beschwerden, die mit krankhaften Veränderungen oder Irritationen der Prostata verbunden sind
US62459004P 2004-11-03 2004-11-03

Publications (1)

Publication Number Publication Date
TW200630083A true TW200630083A (en) 2006-09-01

Family

ID=36202691

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094136193A TW200630083A (en) 2004-10-18 2005-10-17 Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract

Country Status (6)

Country Link
US (1) US20060084700A1 (enExample)
EP (1) EP1804778A1 (enExample)
JP (1) JP2008516909A (enExample)
CA (1) CA2580170A1 (enExample)
TW (1) TW200630083A (enExample)
WO (1) WO2006042679A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
EP1955707A4 (en) * 2005-11-28 2010-09-01 Kissei Pharmaceutical PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NEUROGENIC PAIN
EP2037927B1 (en) 2006-06-30 2010-01-27 Boehringer Ingelheim International GmbH Flibanserin for the treatment of urinary incontinence and related diseases
WO2008121268A1 (en) * 2007-03-29 2008-10-09 Merck & Co., Inc. Combination therapy for the treatment-of lower urinary tract symptoms
IN2012DN02782A (enExample) * 2009-10-07 2015-09-18 Merck Sharp & Dohme
US9522129B2 (en) 2010-08-03 2016-12-20 Velicept Therapeutics, Inc. Pharmaceutical Combination
EA030145B1 (ru) * 2010-08-03 2018-06-29 Велисепт Терапьютикс, Инк. Комбинации агонистов бета-3-адренергических рецепторов и антагонистов мускариновых рецепторов для лечения гиперактивности мочевого пузыря
US9907767B2 (en) 2010-08-03 2018-03-06 Velicept Therapeutics, Inc. Pharmaceutical compositions and the treatment of overactive bladder
EP3226849A4 (en) 2014-12-03 2018-05-09 Velicept Therapeutics, Inc. Compositions and methods of using modified release solabegron for lower urinary tract symptoms
FI3365321T3 (fi) 2015-10-23 2024-01-02 B3Ar Therapeutics Inc Solabegron-Zwitterioni ja sen käyttöjä

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116615A (en) * 1989-01-27 1992-05-26 Immunolytics, Inc. Method for treating benign prostatic hypertrophy
MY126489A (en) * 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
PT1426355E (pt) * 2001-09-13 2008-11-03 Kissei Pharmaceutical Cristais de derivado de hidroxinorefedrina
DE10251170A1 (de) * 2002-10-31 2004-05-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Beta-Agonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
JP2006522144A (ja) * 2003-04-04 2006-09-28 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 下部尿路障害の治療方法
US20050222247A1 (en) * 2003-12-13 2005-10-06 Bayer Healthcare Ag Chroman derivatives

Also Published As

Publication number Publication date
WO2006042679A1 (de) 2006-04-27
US20060084700A1 (en) 2006-04-20
CA2580170A1 (en) 2006-04-27
EP1804778A1 (de) 2007-07-11
JP2008516909A (ja) 2008-05-22

Similar Documents

Publication Publication Date Title
TNSN08147A1 (en) Pde inhibitors and combinations thereof for the treatment of urological disorders
TW200630083A (en) Use of a beta-3 agonist for the treatment of disorders of the prostate and of the lower urogenital tract
EP1887976B8 (en) Devices for treating benign prostatic hyperplasia and other conditions
TW200612918A (en) Lonidamine analogs
WO2010065751A3 (en) Formulations of guanylate cyclase c agonists and methods of use
EP2026877A4 (en) Benign prostatic hyperplasia treatment device and method
WO2008019139A3 (en) Inhibitors of pyruvate kinase and methods of treating disease
WO2005053609A3 (en) Methods of nad+-dependent deacetylase inhibitors
UY28933A1 (es) Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos
MX349787B (es) Formas de dosis oral que incluyen un agente antiplaqueta y un inhibidor de ácido.
CA2334460A1 (en) Pharmaceutical compositions comprising alpha-adrenoceptor antagonists and muscarinic antagonists
WO2007060471A3 (en) Biomarkers and methods for identification of agents useful in the treatment of affective disorders
WO2006102232A3 (en) Dosing regimes for trans-clomiphene
EP1959855A4 (en) TREATMENT OF BENIGNER PROSTATE HYPERPLASIA WITH A PHOTOSENSIBILIZER AND LASER ABLATION
DK1501517T3 (da) Farmaceutisk kombination til behandling af godartet hyperplasia af prostata eller til langtidsforhindring af akut urinretention
UA56965U (ru) Средство для лечения и профилактики доброкачественной гиперплазии предстательной железы, простатита, импотенции, бесплодия и paka предстательной железы
WO2005117979A3 (en) Use of il-17 in the treatment of fertility-related disorders
EP1372639A4 (en) FOR THE TREATMENT OF SYNTHETIC SYMPTOMS WITH COMPLEMENTARY BENIGNER PROSTATE HYPERPLASIA
FR2859910B1 (fr) Utilisation du 1-alpha-fluoro-25-hydroxy-16,23e-diene-26,27- bishomo-20-epi-cholecalciferol pour le traitement de l'hyperplasie benigne de la prostate
WO2006065968A8 (en) The uses of estrogen beta agonists to treat cognitive diseases
DK1427430T3 (da) Anvendelse af ekstrakter af cimicifuga-arter som organselektivt lægemiddel til behandling af seksualhormonafhængige sygdomme i urogenitalsystemet
EP1990048A3 (en) Therapy of benign prostatic hyperplasia (bph)
EP2192903A4 (en) COMPOSITION AND METHOD OF TREATMENT OR METHOD PREVENTING SYMPTOMS BENIGNER PROSTATE HYPERPLASIA AND LOWER HARN
Labrinakos Tradition regained: a study of Sir Richard Rodney Bennett's Partita (1995)
WO2002077162A3 (en) Gene (t23490) associated with benign prostatic hyperplasia